To all you haters

Discussion in 'Cyberonics' started by Anonymous, Aug 19, 2008 at 6:53 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Cyberonics Board of Directors Nominates Joseph E. Laptewicz
    Thursday August 7, 9:18 am ET


    HOUSTON, Aug. 7 /PRNewswire-FirstCall/ -- Cyberonics, Inc. (Nasdaq: CYBX - News) today announced that Joseph E. Laptewicz, Jr. has been nominated to stand for election to its Board of Directors. Mr. Laptewicz will replace Jeffrey E. Schwarz, a director since January 2007, who has announced his intention to resign his seat as of the date of the Annual Meeting on September 25, 2008.
    ADVERTISEMENT


    In commenting on his decision not to stand for re-election, Mr. Schwarz said, "When the Metropolitan Capital nominees joined the Cyberonics board 18 months ago, our goal was to help refocus the company on its core epilepsy franchise, improve corporate governance and chart a course for Cyberonics to return to profitability. Under the leadership of the company's new Chief Executive Officer, Dan Moore, and Chief Financial Officer, Greg Browne, Cyberonics has made great strides and recently achieved our goal of a return to profitability by the end of our recently completed fiscal year. I believe the time is right for me now to step down from the Cyberonics board." Mr. Schwarz continued, "With a strong new management team in place, a dedicated board headed by Hugh Morrison, its Chairman, and with the addition of a director with the stature of Joe Laptewicz, a seasoned medical device executive and director, Cyberonics is poised for future growth, and its prospects are bright."

    Most recently, Mr. Laptewicz served for seven years as a director on the board of Advanced Neuromodulation Systems, Inc., which was acquired by St. Jude Medical, Inc. in 2005. He was a member of that board's audit and governance committees. Prior to this, Mr. Laptewicz was Chairman of Empi, Inc., a leading distributor of electrical stimulation medical products, from 2001 to 2004. He served as the company's President and CEO from 1994 to 2000 and led Empi's acquisition by The Carlyle Group in 1999. Earlier in his career, Mr. Laptewicz held several management positions, including President and Executive Vice President, at Schneider (USA), Inc., the vascular devices unit of Pfizer, Inc. (acquired by Boston Scientific in 1998). In this role, Mr. Laptewicz managed the company's domestic cardiology and radiology businesses.

    "I would like to take this opportunity to thank Jeffrey for his contributions to the Cyberonics turnaround," said Hugh M. Morrison, Chairman of the Board of Cyberonics. "His business acumen has been critical in helping guide our strategic direction. With a core focus on epilepsy and significantly improving financial metrics, the company is well-positioned for long-term success, and adding someone with the substantial industry knowledge that Joe possesses should prove invaluable as Cyberonics continues to grow its business."

    About Cyberonics, Inc. and VNS Therapy(TM)

    Cyberonics, Inc. (NASDAQ:CYBX - News) is a medical technology company with core expertise in neuromodulation. The company developed and markets the Vagus Nerve Stimulation (VNS) Therapy(TM) System, which is FDA-approved for the treatments of refractory epilepsy and depression. The VNS Therapy System uses a surgically implanted medical device that delivers pulsed electrical signals to the vagus nerve. Cyberonics markets the VNS Therapy System in selected markets worldwide.

    Additional information on Cyberonics, Inc. and VNS Therapy(TM) is available at http://www.cyberonics.com and http://www.vnstherapy.com.

    Safe harbor statement

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology, including "may," "believe," "will," "expect," "anticipate," "estimate," "plan," "intend," and "forecast," or other similar words. Statements contained in this press release are based upon information presently available to us and assumptions that we believe to be reasonable. We are not assuming any duty to update this information should those facts change or should we no longer believe the assumptions to be reasonable. Investors are cautioned that all such statements involve risks and uncertainties, including without limitation, statements concerning election of Mr. Laptewicz and the company's strong future growth and long-term success. Our actual results may differ materially. Important factors that may cause actual results to differ include, but are not limited to: continued market acceptance of VNS Therapy and sales of our product; the development and satisfactory completion of clinical trials and/or market test and/or regulatory approval of VNS Therapy for the treatment of other indications; satisfactory completion of post-market studies required by the U.S. Food and Drug Administration as a condition of approval for the treatment-resistant depression indication; adverse changes in coverage or reimbursement amounts by third-parties; intellectual property protection and potential infringement claims; maintaining compliance with government regulations and obtaining necessary government approvals for new indications; product liability claims and potential litigation; reliance on single suppliers and manufacturers for certain components; the accuracy of management's estimates of future expenses and sales; the results of the previously disclosed governmental inquiries; the potential identification of material weaknesses in our internal controls over financial reporting; risks and costs associated with such governmental inquiries and any litigation relating thereto or to our stock option grants, procedures, and practices (including the previously disclosed private litigation); uncertainties associated with stockholder litigation; and other risks detailed from time to time in our filings with the Securities and Exchange Commission (SEC). For a detailed discussion of these and other cautionary statements, please refer to our most recent filings with the SEC, including our Annual Report on Form 10-K for the fiscal year ended April 25, 2008.


    Contact information
    Greg Browne, CFO
    Cyberonics, Inc.
    100 Cyberonics Blvd., Houston, TX 77058
    Main: (281) 228-7262/Fax: (281) 218-9332
    ir@cyberonics.com
     

  2. Anonymous

    Anonymous Guest

    2011 mean anything to you?
     
  3. Anonymous

    Anonymous Guest

    This is the biggest P.O.S. company that exists.
     
  4. Anonymous

    Anonymous Guest

    All this while ignoring the wake of destruction and ruined lives.

    Some bright future!

    Sorry, Skip already raped anything of value this company had to offer.
     
  5. Anonymous

    Anonymous Guest

    The person that started this post desperately needs psychotherapy. Somebody call 911, ASAP!!!


    "we recently received regulatory approval in China and appointed a distributor for that market"

    We can't even do it right in the United States. Now the Steener wants to do business in China. Great idea. Let's try doing business in a Communist
    country with no human rights or civil liberties. By the way, who at CYBX speaks Mandarin Chinese?

    JR is out of control. Management has lost its mind. The stock just loves this business. I think it is at $22.
     
  6. Anonymous

    Anonymous Guest

    This is the worst company that has ever existed. They don't care about killing people or leaving them in a vegatative state, all they care about is the cash, cash, cash. Shame on you, YOU WILL PAY VERY SOON
     
  7. Anonymous

    Anonymous Guest

    I would not implant this device in my dog. I agree, 2011 is coming and then all the corrupt pigs in this company can go slop around in the mud together. They have NOTHING to be proud of, nothing! They certainly do not care a flip about the patients. Where is the FDA? They come in, stuff their faces for a week and then leave.
     
  8. Anonymous

    Anonymous Guest

    Cool
     
  9. Anonymous

    Anonymous Guest

    OP seems to think a press release made months ago will change fact.


    Tut, tut, tut...Dear OP, press releases, just like "success stories" and foo-foo articles are only a facade. They sway those desperate for help, placate stock holders and are the very foundations that idiots and shills base their faith.

    CYBX threw out "truth in advertising" years ago. It's all about covering their asses, and grubbing the almighty dollar. Get one implanted and find out for yourself.
     
  10. Anonymous

    Anonymous Guest

    Rock on Dispatch
     
  11. Anonymous

    Anonymous Guest

    not posted by dispatch, but yeah, rock on dispatch

    and dennis
    and shannon
    and jeanne
    and donna
    and nancyb
    and nanci wilson
    and chuck grassley
    and soon there will be more to add to the rock on list

    CAN'T WAIT...ROCK ON!
     
  12. Anonymous

    Anonymous Guest

    Soon.

    That list will contain names of notoriety.

    Soon Cyberonics and all those associated will reap the whirlwind.

    Soon.
     
  13. Anonymous

    Anonymous Guest

    Cool
     
  14. Anonymous

    Anonymous Guest

    rock on dennis :)
     
  15. Anonymous

    Anonymous Guest

    You should go to sharedsymptoms.com. This is a good place to discuss these types of issues
     
  16. Anonymous

    Anonymous Guest

    Shut up Herb crawl back under your rock.
     
  17. Anonymous

    Anonymous Guest

    We'll find out in a month or so.
     
  18. Anonymous

    Anonymous Guest

    Margaret Hamburg ROCKS !!!!!!!!!
     
  19. Anonymous

    Anonymous Guest

    Baader Bank AG is a securities trading bank [Akteingesellschaft] It engages in the securities trading operations. It is the largest independent securities trading company in Germany [based in Bavaria] What are some advantages of investing in foreign securities/ 1] income taxes are withheld on the income earned from an investment in a foreign security, the taxes withheld can be deducted on the Investors' United States tax return. Fluctuations in foreign currency could change the total return on the investment for the better. Because income taxes are withheld on the income earned from an investment in a foreign security, the taxes withheld can be deducted on the investors' United States tax return. http://www.boerse-frankfurt.de/DE/Medial pg 37/383JC8 US 23251P1021 CYBERONICS INC. DL., -01 BAADERBANK AKTIENGESELLSCHAFT bfu 4fp zs3
     
  20. Anonymous

    Anonymous Guest

    NancyB rocks !!!!!!!!!!!!!!!!!!!!!!!!!!!